NewAmsterdam Pharma Company N.V. (NAMSW) Net income 2021–2025
NewAmsterdam Pharma Company N.V. (NAMSW) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$203.8MFY2025 · since FY2021: -$41.8M → -$203.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$203.8M | +15.6% |
| FY2024 | -$241.6M | -36.5% |
| FY2023 | -$176.9M | -681.7% |
| FY2022 | -$22.6M | +45.8% |
| FY2021 | -$41.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net marginNAMSW Gross profitNAMSW Gross marginNAMSW Operating incomeNAMSW Operating marginNAMSW Operating cash flowNAMSW Free cash flowNAMSW Capital expendituresNAMSW Return on equityNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Total liabilitiesNAMSW Shareholders’ equityNAMSW overview →